Third, the usage of various PAH models (sugen/hypoxia, MCT, and PAB), as well as initiation, duration, and frequency of treatment, may affect the results of HDAC inhibitors in experimental models. This evidence concerns the gene HDAC9 and pulmonary arterial hypertension.